Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas A Wilkinson

Showing results (11-20 of 15) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 15 results.
Cells|November 14, 2020
Integrated Single-Cell RNA-Sequencing Analysis of Aquaporin 5-Expressing Mouse Lung Epithelial Cells Identifies GPRC5A as a Novel Validated Type I Cell Surface MarkerMasafumi Horie, Alessandra Castaldi, Mitsuhiro Sunohara, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|December 16, 2024
Bleed treatment with eptacog beta (rFVIIa) results in a low incidence of rebleeding in adult and adolescent patients with haemophilia A or B with inhibitorsAmy Dunn, Yesim Dargaud, Yasmina Abajas, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|October 6, 2021
PERSEPT 3: A phase 3 clinical trial to evaluate the haemostatic efficacy of eptacog beta (recombinant human FVIIa) in perioperative care in subjects with haemophilia A or B with inhibitorsMiguel Escobar, James Luck, Yevhenii Averianov, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|October 12, 2021
The safety of activated eptacog beta in the management of bleeding episodes and perioperative haemostasis in adult and paediatric haemophilia patients with inhibitorsMiguel Escobar, Giancarlo Castaman, Santiago Bonanad Boix, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|April 27, 2022
Eptacog beta efficacy and safety in the treatment and control of bleeding in paediatric subjects (<12 years) with haemophilia A or B with inhibitorsSteven W Pipe, Cédric Hermans, Meera Chitlur, et al.
Pageof 2

Showing results (11-20 of 15) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 15 results.
Cells|November 14, 2020
Integrated Single-Cell RNA-Sequencing Analysis of Aquaporin 5-Expressing Mouse Lung Epithelial Cells Identifies GPRC5A as a Novel Validated Type I Cell Surface MarkerMasafumi Horie, Alessandra Castaldi, Mitsuhiro Sunohara, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|December 16, 2024
Bleed treatment with eptacog beta (rFVIIa) results in a low incidence of rebleeding in adult and adolescent patients with haemophilia A or B with inhibitorsAmy Dunn, Yesim Dargaud, Yasmina Abajas, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|October 6, 2021
PERSEPT 3: A phase 3 clinical trial to evaluate the haemostatic efficacy of eptacog beta (recombinant human FVIIa) in perioperative care in subjects with haemophilia A or B with inhibitorsMiguel Escobar, James Luck, Yevhenii Averianov, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|October 12, 2021
The safety of activated eptacog beta in the management of bleeding episodes and perioperative haemostasis in adult and paediatric haemophilia patients with inhibitorsMiguel Escobar, Giancarlo Castaman, Santiago Bonanad Boix, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|April 27, 2022
Eptacog beta efficacy and safety in the treatment and control of bleeding in paediatric subjects (<12 years) with haemophilia A or B with inhibitorsSteven W Pipe, Cédric Hermans, Meera Chitlur, et al.
Pageof 2